Provided by Tiger Fintech (Singapore) Pte. Ltd.

MaxCyte Inc

2.57
-0.0400-1.53%
Post-market: 2.570.00000.00%16:33 EDT
Volume:545.52K
Turnover:1.41M
Market Cap:273.23M
PE:-6.56
High:2.68
Open:2.57
Low:2.53
Close:2.61
Loading ...

MaxCyte reports Q4 EPS (10c), consensus (12c)

TIPRANKS
·
12 Mar

MaxCyte sees FY25 core business revenue up 8%-15%

TIPRANKS
·
12 Mar

MaxCyte Q4 2024 GAAP EPS $(0.10) Beats $(0.12) Estimate, Sales $8.693M Beat $7.993M Estimate

Benzinga
·
12 Mar

MaxCyte Inc Qtrly Loss per Share $0.10

THOMSON REUTERS
·
12 Mar

MaxCyte Inc Q4 Shr View $-0.12 -- Lseg Ibes Data

THOMSON REUTERS
·
12 Mar

MaxCyte Inc Outlook Core Revenue Is Expected to Grow 8% to 15% in 2025 Compared to 2024

THOMSON REUTERS
·
12 Mar

BRIEF-MaxCyte Q4 Revenue USD 8.7 Million Vs. IBES Estimate USD 7.93 Million

Reuters
·
12 Mar

MaxCyte Q4 Gross Profit USD 6.4 Million

THOMSON REUTERS
·
12 Mar

MaxCyte Q4 Adjusted Ebitda USD -11.8 Million

THOMSON REUTERS
·
12 Mar

MaxCyte Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
08 Mar

MaxCyte Expands Stock Capital with New Issuance

TIPRANKS
·
04 Mar

MaxCyte Experiences Shift in Major Holdings by BlackRock

TIPRANKS
·
15 Feb

BlackRock Increases Stake in MaxCyte to 7.66%

TIPRANKS
·
14 Feb

BlackRock Adjusts Holdings in MaxCyte, Inc.

TIPRANKS
·
13 Feb

Craig-Hallum Sticks to Their Buy Rating for MaxCyte (MXCT)

TIPRANKS
·
13 Feb

MaxCyte enters strategic platform license with TG Therapeutics

TIPRANKS
·
12 Feb

MaxCyte Licenses Cell-Engineering Technology to TG Therapeutics

MT Newswires Live
·
12 Feb

BRIEF-Maxcyte Says Enters Strategic Platform License With TG Therapeutics

Reuters
·
12 Feb

MaxCyte Signs Strategic Platform License With TG Therapeutics to Advance Its Autoimmune Cell Therapeutics Programs

THOMSON REUTERS
·
12 Feb

MaxCyte Inc - Enters Strategic Platform License With TG Therapeutics

THOMSON REUTERS
·
12 Feb